PF 6412562

Drug Profile

PF 6412562

Alternative Names: PF-06412562; PF-6412562

Latest Information Update: 13 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antiparkinsonians; Nootropics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cognition disorders; Parkinson's disease; Schizophrenia

Most Recent Events

  • 08 May 2017 University of Zurich initiates enrolment in a phase I trial in Healthy volunteers in Switzerland (NCT03181841)
  • 01 Nov 2016 Discontinued - Phase-I for Cognition disorders (In volunteers) in Belgium, Sweden (PO) (Pfizer pipeline, February 2017)
  • 01 Nov 2016 Discontinued - Phase-I for Cognition disorders (In volunteers) in USA (PO) (Pfizer pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top